Literature DB >> 14584070

The prognostic impact of cyclin dependent kinase inhibitors p21WAF1, p27Kip1, and p16INK4/MTS1 in adenocarcinomas of the uterine cervix: an immunohistochemical evaluation of expression patterns in population-based material from 142 patients with international federation of gynecology and obstetrics stage I and II adenocarcinoma.

G Cecilie Alfsen1, Wenche Reed, Berit Sandstad, Gunnar B Kristensen, Vera M Abeler.   

Abstract

BACKGROUND: The authors assessed the prognostic significance of abnormal cyclin dependent kinase inhibitor (CDKI) expression in adenocarcinomas of the uterine cervix.
METHODS: Population-based, archival material from patients with International Federation of Gynecology and Obstetrics (FIGO) Stage I and II cervical adenocarcionmas from 2 5-year periods (1976-1980, n = 82 patients; 1986-1990, n = 142 patients) was examined for expression of p21(WAF1), p27(Kip1), and p16(INK4/MTS1) using immunohistochemical techniques.
RESULTS: Rates of tumors with low levels of nuclear expression of p27 and p16 were lower during the period 1976-1980 (P < 0.01), suggesting bias due to unbuffered formalin. Analyses that were restricted to patients from 1986-1990 showed positive associations between all three CDKIs (P < 0.05). Low p16 expression was associated with higher FIGO stage (P = 0.01), age older than 55 years (P = 0.01), and deep invasion (P = 0.003). No significant associations with stage, age, or histopathologic parameters were found for p21 or p27. Significant associations with tumor differentiation were not seen for any CDKI. Kaplan-Meier plots showed diverging survival curves for p21 and p27 expression, but the differences were not significant. In multivariate analysis, low p27 expression and high p16 expression were strong predictors of a poor prognosis (p27: < 40% nuclear staining; P = 0.001; hazard ratio, 3.18; p16: < 40% nuclear staining; P < 0.001; hazard ratio, 0.16). Low p27 expression was of prognostic significance only if it was analyzed together with p16 expression. Further evaluation indicated that patients with different phenotypic p27/p16 combinations may have different outcomes.
CONCLUSIONS: Aberrant expression patterns of CDKIs were predictors of prognosis for patients with FIGO Stage I or II cervical adenocarcinoma. Analysis of CDKI expression in this patient group may prove clinically useful. Copyright 2003 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14584070     DOI: 10.1002/cncr.11727

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  Type C2 radical hysterectomy may improve outcomes of locally advanced mucinous adenocarcinoma of the uterine cervix.

Authors:  Shinichi Okame; Atsumi Kojima; Norihiro Teramoto; Yuko Shiroyama; Takashi Yokoyama; Kazuhiro Takehara; Takayoshi Nogawa
Journal:  Int J Clin Oncol       Date:  2015-12-22       Impact factor: 3.402

Review 2.  p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis.

Authors:  I Tsoumpou; M Arbyn; M Kyrgiou; N Wentzensen; G Koliopoulos; P Martin-Hirsch; V Malamou-Mitsi; E Paraskevaidis
Journal:  Cancer Treat Rev       Date:  2009-03-03       Impact factor: 12.111

3.  PRIMA-1MET Induces Cellular Senescence and Apoptotic Cell Death in Cholangiocarcinoma Cells.

Authors:  Chayanit Piyawajanusorn; Yingpinyapat Kittirat; Prakasit Sa-Ngiamwibool; Attapol Titapun; Watcharin Loilome; Nisana Namwat
Journal:  Cancer Genomics Proteomics       Date:  2019 Nov-Dec       Impact factor: 4.069

Review 4.  Prognostic significance of overexpressed p16INK4a in patients with cervical cancer: a meta-analysis.

Authors:  Jiaying Lin; Andreas E Albers; Jinbao Qin; Andreas M Kaufmann
Journal:  PLoS One       Date:  2014-09-04       Impact factor: 3.240

5.  Clinicopathological characteristics and prognostic factors of cervical adenocarcinoma.

Authors:  Min Wang; Bo Yuan; Zhen-Huan Zhou; Wei-Wei Han
Journal:  Sci Rep       Date:  2021-04-05       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.